Luísa Viterbo

934 total citations
19 papers, 235 citations indexed

About

Luísa Viterbo is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Luísa Viterbo has authored 19 papers receiving a total of 235 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 10 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in Luísa Viterbo's work include Multiple Myeloma Research and Treatments (8 papers), Acute Myeloid Leukemia Research (7 papers) and Protein Degradation and Inhibitors (5 papers). Luísa Viterbo is often cited by papers focused on Multiple Myeloma Research and Treatments (8 papers), Acute Myeloid Leukemia Research (7 papers) and Protein Degradation and Inhibitors (5 papers). Luísa Viterbo collaborates with scholars based in Portugal, United States and Czechia. Luísa Viterbo's co-authors include Tamás Masszi, Helgi van de Velde, Richard Greil, Ivan Špıčka, Anna Dmoszyńska, Deborah Berg, Huaibao Feng, Paul G. Richardson, Heinz Ludwig and Ofer Shpilberg and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Critical Care.

In The Last Decade

Luísa Viterbo

17 papers receiving 228 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Luísa Viterbo Portugal 8 203 163 109 31 21 19 235
Pia Sondergeld Germany 4 220 1.1× 139 0.9× 135 1.2× 40 1.3× 8 0.4× 4 252
Gabriela Borsaru Romania 7 111 0.5× 105 0.6× 38 0.3× 28 0.9× 9 0.4× 11 169
Joaquín Díaz Mediavilla Spain 6 162 0.8× 125 0.8× 87 0.8× 35 1.1× 7 0.3× 8 201
Ma Teresa Cibeira Spain 8 272 1.3× 224 1.4× 153 1.4× 51 1.6× 20 1.0× 13 306
Laurie Kenvin United States 6 265 1.3× 203 1.2× 115 1.1× 51 1.6× 25 1.2× 10 297
Alexandra Jungová Czechia 6 95 0.5× 60 0.4× 56 0.5× 35 1.1× 16 0.8× 35 130
Catherine McGuinn United States 8 132 0.7× 58 0.4× 55 0.5× 33 1.1× 10 0.5× 23 191
Steven Richebourg France 6 218 1.1× 122 0.7× 57 0.5× 68 2.2× 32 1.5× 10 256
Ulrich Germing Germany 3 193 1.0× 121 0.7× 36 0.3× 60 1.9× 41 2.0× 3 228
Holly Lee Canada 9 100 0.5× 99 0.6× 94 0.9× 15 0.5× 6 0.3× 37 187

Countries citing papers authored by Luísa Viterbo

Since Specialization
Citations

This map shows the geographic impact of Luísa Viterbo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luísa Viterbo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luísa Viterbo more than expected).

Fields of papers citing papers by Luísa Viterbo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luísa Viterbo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luísa Viterbo. The network helps show where Luísa Viterbo may publish in the future.

Co-authorship network of co-authors of Luísa Viterbo

This figure shows the co-authorship network connecting the top 25 collaborators of Luísa Viterbo. A scholar is included among the top collaborators of Luísa Viterbo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luísa Viterbo. Luísa Viterbo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Viterbo, Luísa, et al.. (2023). Arterial Blood Gas, Electrolyte and Acid-Base Values as Diagnostic and Prognostic Indicators in Equine Colic. Animals. 13(20). 3241–3241. 4 indexed citations
2.
Oliveira, Isabel, Nélson Domingues, Luísa Viterbo, et al.. (2021). Gastric MALT Lymphoma: A 8-Year Experience. Indian Journal of Hematology and Blood Transfusion. 38(3). 492–498.
3.
Oliveira, Isabel, Nélson Domingues, Luísa Viterbo, et al.. (2021). Gastric Diffuse Large B-Cell Lymphoma: A Single-Center 9-Year Experience. Indian Journal of Hematology and Blood Transfusion. 37(3). 492–496. 5 indexed citations
4.
Cerveira, Nuno, Susana Bizarro, Cecília Correia, et al.. (2018). Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution. BMC Cancer. 18(1). 1245–1245. 15 indexed citations
5.
6.
Ferreira, Isabel C.F.R., Luís Leite, Cláudia Moreira, et al.. (2017). Southwestern Oncology Group pretreatment risk criteria as predictive or prognostic factors in acute myeloid leukemia. Molecular and Clinical Oncology. 6(3). 384–388. 3 indexed citations
7.
8.
Ferreira, Isabel C.F.R., Luís Leite, Cláudia Moreira, et al.. (2016). Effect of therapy-related acute myeloid leukemia on the outcome of patients with acute myeloid leukemia. Oncology Letters. 12(1). 262–268. 8 indexed citations
9.
Mateos, María‐Victoria, Tamás Masszi, Norbert Grząśko, et al.. (2016). Impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in TOURMALINE-MM1.. Journal of Clinical Oncology. 34(15_suppl). 8039–8039. 4 indexed citations
10.
Richardson, Paul G., Hervé Avet‐Loiseau, Antonio Palumbo, et al.. (2016). Efficacy and safety of ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) by cytogenetic risk status in the global phase III Tourmaline-MM1 study.. Journal of Clinical Oncology. 34(15_suppl). 8018–8018. 7 indexed citations
11.
Ludwig, Heinz, Richard Greil, Tamás Masszi, et al.. (2015). Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up. British Journal of Haematology. 171(3). 344–354. 21 indexed citations
12.
Ludwig, Heinz, Luísa Viterbo, Richard Greil, et al.. (2012). Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma. Journal of Clinical Oncology. 31(2). 247–255. 58 indexed citations
13.
Cerveira, Nuno, Susana Lisboa, Cecília Correia, et al.. (2012). Genetic and clinical characterization of 45 acute leukemia patients with MLL gene rearrangements from a single institution. Molecular Oncology. 6(5). 553–564. 13 indexed citations
14.
Mesquita, Edgar, Nélson Domingues, Isabel Oliveira, et al.. (2012). Prognostic Impact of High Hematogones in Acute Myeloid Leukemia. Blood. 120(21). 1435–1435. 2 indexed citations
15.
Cerveira, Nuno, Susana Lisboa, Cecília Correia, et al.. (2012). Genetic and Clinical Characterization of 45 Acute Leukemia Patients with MLL Gene Rearrangements From a Single Institution.. Blood. 120(21). 2477–2477.
16.
Santos, Joana, Nuno Cerveira, Cecília Correia, et al.. (2010). Coexistence of alternative MLL–SEPT9 fusion transcripts in an acute myeloid leukemia with t(11;17)(q23;q25). Cancer Genetics and Cytogenetics. 197(1). 60–64. 10 indexed citations
17.
Ludwig, Heinz, Luísa Viterbo, Richard Greil, et al.. (2010). Phase II study of bortezomib, thalidomide, and dexamethasone /- cyclophosphamide as induction therapy in previously untreated multiple myeloma (MM): safety and activity including evaluation of MRD. 4 indexed citations
18.
19.
Faria, Fábio Silva, et al.. (1999). Retrospective study of patients with haematological malignancies admitted in an intensive care unit. Critical Care. 3(Suppl 1). P238–P238. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pia Sondergeld Breakdown of academic impact, for papers by Gabriela Borsaru Breakdown of academic impact, for papers by Joaquín Díaz Mediavilla Breakdown of academic impact, for papers by Ma Teresa Cibeira Breakdown of academic impact, for papers by Laurie Kenvin Breakdown of academic impact, for papers by Alexandra Jungová Breakdown of academic impact, for papers by Catherine McGuinn Breakdown of academic impact, for papers by Steven Richebourg Breakdown of academic impact, for papers by Ulrich Germing Breakdown of academic impact, for papers by Holly Lee
Rankless by CCL
2026